Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of a malignant disorder (hematologic malignancies or solid tumors)
• * Advanced disease
• Has undergone prior allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-mismatched/haploidentical familial donor
• Progressive or recurrent disease, as defined by any of the following (phase II):
• * Peripheral blood blast \> 20% with bone marrow aspirate showing \> 5% leukemic cells (in patients with acute leukemia)
• * Detection of metaphases in the marrow with the same clonal cytogenetic abnormalities as identified before HSCT (or by FISH markers, if appropriate) (in patients with acute leukemia or high-risk myelodysplastic syndromes \[MDS\])
• * Persistent cytopenia with bone marrow aspirate showing various degrees of dysplasia involving ≥ 1 cell lineage (in patients with high-risk MDS)
• * Enlargement of pre-existing measurable lesions by 20% according to RECIST criteria (in patients with solid tumors or lymphoma)
• * Appearance of new metastatic lesions, including pleural effusion or ascites, radiologically typical for metastases or confirmed as such by cytology (in patients with solid tumors or lymphoma)
• Measurable disease (phase II)
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 70-100%
• Total bilirubin \< 3.0 mg/dL
• AST \< 5 times upper limit of normal
• Creatinine \< 3 mg/dL
• Not pregnant or nursing
• No clinically evident cardiac or pulmonary failure
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics